the construction of a vaccinia virus mutant which lacks a functional VGF gene. The VGFmutant replicated less efficiently than did the wild-type (WT) virus in resting Swiss 3T3 cells and exhibited an attenuated phenotype following intracranial (i.c.) and intradermal inoculations into mice and rabbits, respectively. MATERIALS AND METHODS Cells and viruses. The vaccinia virus WR strain, originally obtained from the American Type Culture Collection Rockville, Md., was propagated in HeLa cells and purified as reported previously (22). CV-1 and Swiss 3T3 cells were grown in Dulbecco modified Eagle medium (DMEM; Quality Biologic Inc.) supplemented with 10% fetal bovine serum (FBS). A431 human epitheloid carcinoma cells, which have a high density of EGF receptors on the cell surface, were grown in DMEM supplemented with 5% FBS or 10% bovine serum (14). BS-C-1 cells were grown in minimum essential medium (MEM; GIBCO Laboratories) containing 10% FBS. Enzymes and chemicals. Restriction enzymes were supplied by Bethesda Research Laboratories, Inc., Gaithersburg, Md., New England BioLabs, Inc., Beverly, Mass., or Boehringer Mannheim Biochemicals, Indianapolis, Ind., and used as specified by the manufacturers. The Klenow fragment of DNA polymerase I, T4 DNA ligase, 5-bromo-4chloro-3-indolyl- ,-D-galactopyranoside (X-Gal), and isopropyl-j3-D-thiogalactopyranoside (IPTG) were obtained from Boehringer Mannheim. The BglII linker was purchased from New England BioLabs, and EGF was obtained from Collaborative Research, Inc., Waltham, Mass. Animals. Male BALB/cByJ and A/J mice between 6 and 10 weeks of age were obtained from Jackson Laboratory, Bar Harbor, Maine. Outbred black rabbits of both sexes were obtained from Spring Valley Laboratories. Guidelines in the National Institutes of Health "Guide for the Care and Use of Laboratory Animals" were followed for animal husbandry. Virus infectivity assays. Virus infectivity was estimated as 866